Fertility and sterility · 2011
Body mass index-associated differences in response to ovulation induction with letrozole.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McKnight Katherine K, Nodler James L, Cooper John J, Chapman Victoria R, Cliver Suzanne P, Bates Gordon Wright
Аннотация
OBJECTIVE: To compare occurrence of pregnancy among obese (body mass index [BMI] ≥30) and nonobese (BMI <30), infertile women undergoing ovulation induction with the aromatase inhibitor letrozole followed by intrauterine insemination (IUI).
DESIGN: Retrospective cohort study.
SETTING: Academic reproductive endocrinology and infertility clinic.
PATIENT(S): Ninety women with a variety of infertility diagnoses.
INTERVENTION(S): Letrozole (5 mg) on menstrual cycle days 3-7, followed by intrauterine insemination (IUI).
MAIN OUTCOME MEASURE(S): Occurrence of pregnancy and pregnancy outcomes.
RESULT(S): Ninety women underwent 180 letrozole-IUI cycles. Conception of pregnancy occurred in 10.4% and 18.2% of the BMI <30 and BMI ≥30 groups, respectively. Using BMI as a continuous variable showed a pregnancy odds ratio of 1.093 (confidence interval 1.008-1.184) for each unit increase in BMI. Incidence of miscarriage, multiple births, number of mature follicles, and presence of LH surge were similar between groups.
CONCLUSION(S): Our study of 90 women undergoing letrozole-IUI treatment showed greater likelihood of pregnancy in higher-BMI women, although the difference was not significant. Letrozole is an effective ovulation induction agent in higher-BMI women.
DESIGN: Retrospective cohort study.
SETTING: Academic reproductive endocrinology and infertility clinic.
PATIENT(S): Ninety women with a variety of infertility diagnoses.
INTERVENTION(S): Letrozole (5 mg) on menstrual cycle days 3-7, followed by intrauterine insemination (IUI).
MAIN OUTCOME MEASURE(S): Occurrence of pregnancy and pregnancy outcomes.
RESULT(S): Ninety women underwent 180 letrozole-IUI cycles. Conception of pregnancy occurred in 10.4% and 18.2% of the BMI <30 and BMI ≥30 groups, respectively. Using BMI as a continuous variable showed a pregnancy odds ratio of 1.093 (confidence interval 1.008-1.184) for each unit increase in BMI. Incidence of miscarriage, multiple births, number of mature follicles, and presence of LH surge were similar between groups.
CONCLUSION(S): Our study of 90 women undergoing letrozole-IUI treatment showed greater likelihood of pregnancy in higher-BMI women, although the difference was not significant. Letrozole is an effective ovulation induction agent in higher-BMI women.
Предметные рубрики MeSH
AdultAlabamaAromatase InhibitorsBody Mass IndexChi-Square DistributionFemaleFertility Agents, FemaleHumansInfertility, FemaleInsemination, ArtificialLetrozoleLogistic ModelsNitrilesObesityOdds RatioOvaryOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTreatment OutcomeTriazoles